Abstract

Main recommendations:

  • The HAS concludes that the Covid-19 Janssen vaccine is effective against symptomatic forms of Covid-19, in particular against severe / critical forms and hospitalizations, the effectiveness however still to be confirmed on mortality as well as on infection and viral transmission.
  • The HAS considers that the Covid-19 Janssen vaccine can be used from the age of 18 as part of its conditional marketing authorization and the French vaccine strategy with regard to Covid-19 defined by the HAS, including in people aged 65 and over and / or with comorbidities, due to its vaccine efficacy and its satisfactory safety profile.
  • The HAS also considers that the single-dose vaccination schedule and the storage conditions for this vaccine make it particularly suitable for the groups furthest from the health system, people in economic and social precarious situations, and people with disabilities or having difficulty getting around.
  • Recommendation
  • Europe
  • France
  • Janssen COVID-19 Vaccine
  • COVID-19